640P Efficacy and safety of EPI-321, an investigational single dose epigenome editing therapy targeting D4Z4 in facioscapulohumeral Muscular Dystrophy (FSHD)

A Adhikari,S Boregowda,H Zheng,V Agrawal,A Norton,N Wasala,A Collin De L'Hortet

doi:10.1016/j.nmd.2024.07.383

640P Efficacy and safety of EPI-321, an investigational single dose epigenome editing therapy targeting D4Z4 in facioscapulohumeral Muscular Dystrophy (FSHD)

A Adhikari, S Boregowda + Show 5 more

https://doi.org/10.1016/j.nmd.2024.07.383

Copy DOI

Export

Save

Cite

Journal: Neuromuscular Disorders

Publication Date: Oct 1, 2024

#Facioscapulohumeral Muscular Dystrophy #Single Editing #Single Therapy #Epigenome Editing #Muscular Dystrophy #Single Dose

Abstract
Full-Text
Similar Papers

Abstract

Listen

640P Efficacy and safety of EPI-321, an investigational single dose epigenome editing therapy targeting D4Z4 in facioscapulohumeral Muscular Dystrophy (FSHD)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Neuromuscular Disorders

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

640P Efficacy and safety of EPI-321, an investigational single dose epigenome editing therapy targeting D4Z4 in facioscapulohumeral Muscular Dystrophy (FSHD)